Global Breast Cancer Therapeutics Market : Industry Analysis and Forecast (2019-2026) _ by Drug Class (HER2 Inhibitors, Mitotic Inhibitors, Anti-metabolites, Aromatase Inhibitors, and Hormone Receptor Agonist/Antagonist), by Technology (Chemotherapy, Radiation Therapy, Hormone Therapy, and Biotherapy), and by Geography

Global Breast Cancer Therapeutics Market size is expected to grow at a CAGR of 12.9% during the forecast period and the market size is expected to reach nearly US$ 55.2 Bn. by 2026. The report includes the analysis of impact of COVID-19 lock-down on the revenue of market leaders, followers, and disrupters. Since lock down was implemented differently in different regions and countries, impact of same is also different by regions and segments. The report has covered the current short term and long term impact on the market, same will help decision makers to prepare the outline for short term and long term strategies for companies by region. Global Breast Cancer Therapeutics Market To know about the Research Methodology:-Request Free Sample Report

Global Breast Cancer Therapeutics Market Dynamics:

The key drivers in the market growth includes an increase in adoption of therapeutics pertaining to factors such as the risk of distant reappearance, blocking estrogen from binding to tumor cells and risk of developing the disease in another breast. The industry size is expected to be driven by a rise in western lifestyle adoption, increase in awareness regarding breast cancer, rising prevalence of obesity in women post menopause and short breastfeeding timeframe. Targeted drug therapy held the highest share in the Global Breast Cancer Therapeutics Market in 2019. Targeted drug therapy is expected to lead the growth in the coming years because of factors like stopping the growth of new blood vessels, triggering immune system and changing proteins. Chemotherapy segment is expected to see low growth because of the increased cost associated with drugs that put a financial burden on the patient and reactions of chemotherapy resulting in multi-drug resistance.

Global Breast Cancer Therapeutics Market Regional Analysis:

The USA had the largest share in the Global Breast Cancer Therapeutics Market in 2019 due to increased awareness and increased funding in Research and Development. Poland market is expected to grow with the highest CAGR over the forecast period. The Asia Pacific will grow at a substantial pace pertaining to factors like increasing cases of the disease, western lifestyle becoming popular and adoption of advanced technology. Rise in Research and Development funding for innovative drugs, high frequency of CSR activities carried out by corporates for awareness of breast cancer, mergers and acquisition are the key driving factors for the Global Breast Cancer Therapeutics Market over the forecast period.

Global Breast Cancer Therapeutics Market Research Methodology:

Bloomberg, Factiva, and Hoovers are some of the sites that are being referred to gain insights about Global Breast Cancer Therapeutics Market. Experts from top manufacturing companies along with other stakeholders have been considered. This is done to validate and collect critical information for evaluating trends related to this market during the forecast period. Top-down and bottom-up approaches have been used to estimate the global and regional size of this market. Data triangulation techniques along with other comparative analysis are also used to calculate the exact size of the Global Breast Cancer Therapeutics Market globally.

Global Breast Cancer Therapeutics Market, Key Highlights:

• Global Breast Cancer Therapeutics Market analysis and forecast, in terms of value. • Comprehensive study and analysis of market drivers, restraints and opportunities influencing the growth of the Global Breast Cancer Therapeutics Market • Global Breast Cancer Therapeutics Market segmentation on the basis of type, source, end-user, and region (country-wise) has been provided. • Global Breast Cancer Therapeutics Market strategic analysis with respect to individual growth trends, future prospects along with the contribution of various sub-market stakeholders have been considered under the scope of study. • Global Breast Cancer Therapeutics Market analysis and forecast for five major regions namely North America, Europe, Asia Pacific, the Middle East & Africa (MEA) and Latin America along with country-wise segmentation. • Profiles of key industry players, their strategic perspective, market positioning and analysis of core competencies are further profiled. • Competitive developments, investments, strategic expansion and competitive landscape of the key players operating in the Global Breast Cancer Therapeutics Market are also profiled. The report has considered the base year of 2019 and past four years trend. 2020 figures are at actuals, however due to different dynamics of year 2020, market forecast is not only dependent upon 2020, but on the basis of 2016-2020.

Global Breast Cancer Therapeutics Market Key Highlights:

• Overview of key market forces driving market growth • Comprehensive analyses of technological advancements and market trends • Complete analyses of market competition dynamics • Competitors Strategy Analysis • Graphical and SWOT analysis of industry segments • Up-to-date analyses of industry trends • Well-defined technological growth map

Global Breast Cancer Therapeutics Market Research Methodology:

Bloomberg, Factiva, and Hoovers are some of the sites that are being referred to gain insights about Global Breast Cancer Therapeutics Market. Experts from top manufacturing companies along with other stakeholders have been considered. This is done to validate and collect critical information for evaluating trends related to this market during the forecast period. Top-down and bottom-up approaches have been used to estimate the global and regional size of this market. Data triangulation techniques along with other comparative analysis are also used to calculate the exact size of the Global Breast Cancer Therapeutics Market globally.

Some of the major players operating in the Global Breast Cancer Therapeutics Market are as follows:

• AstraZeneca • Eisai Co., Ltd • Eli Lilly • Roche Diagnostics • Novartis AG • Pfizer • Celgene • Sanofi • Teva Pharmaceutical • Bristol-Myers Squibb Co. • Merck & Co. Inc. • Medivation Inc. • GlaxoSmithKline Plc. • F. Hoffmann-La Roche Ltd. • Puma Biotechnology • Genentech • Fresenius kabi • AbbVie, Inc. • Johnson & Johnson • Astellas Pharma, Inc. • Bayer AG • Takeda Pharmaceutical Company Limited

Key Target Audience:

• Breast Cancer Treatment Drugs Manufacturers • Group Purchase Organizations (GPOs) • Distributors of Breast Cancer Drugs • Hospitals and Clinics • Healthcare Institutions • Research Institutes • Market Research and Consulting Firms

Years considered to estimate the market size of the Global Breast Cancer Therapeutics Market are as follows:

• Base year - 2018 • Estimated year - 2019 • Forecast period - 2019 to 2024

The scope of Global Breast Cancer Therapeutics Market:  Inquire before buying

Research report categorizes the Global Breast Cancer Therapeutics Market-based drug class, technology, and geography (region wise). Market size by value is estimated and forecasted with the revenues of leading companies operating in the Global Breast Cancer Therapeutics Market with key developments in companies and market trends.

Global Breast Cancer Therapeutics Market, by Drug Class:

• HER2 Inhibitors • Mitotic Inhibitors • Anti-metabolites • Aromatase Inhibitors • Hormone Receptor Agonist/Antagonist

Global Breast Cancer Therapeutics Market, by Technology:

• Chemotherapy Alkylating Agents Cytotoxic agents Antimetabolites Plant derivatives Others • Radiation Therapy o Intraoperative radiotherapy, o External beam radiation therapy o Brachytherapy o Radioisotope therapy • Hormone Therapy o Hormone Antagonists o Corticosteroids o Aromatase inhibitor o Selective estrogen receptor modulators (SERMs) • Biotherapy o Monoclonal antibodies o Interleukin o Kinases o Others

Global Breast Cancer Therapeutics Market, by Geography:

• North America o The U.S. o Canada • Europe o Germany o France o U.K. o Italy o Spain o Russia o Rest of Europe (RoE) • Asia-Pacific (APAC) o Japan o China o India o Rest of Asia-Pacific (RoAPAC) • Latin America o Brazil o Argentina o Rest of Latin America (RoLA) • The Middle East and Africa o South Africa o Rest of the Middle East and Africa
1. PREFACE 1.1 Report Description 1.2 Market Segmentation 1.3 Research Methodology 2. EXECUTIVE SUMMARY 2.1 Global Breast Cancer Therapeutics: Market Snapshot 2.2 Global Breast Cancer Therapeutics Market Share, by Geography 2.3 Global Breast Cancer Therapeutics Market, by Drug type 2.4 Global Breast Cancer Therapeutics Market Share, by Technology 3. GLOBAL BREAST CANCER THERAPEUTICS MARKET OVERVIEW 3.1 Market Definition and Overview 3.2 Epidemiology & High Risk Groups 3.3 Diagnosis and Types of Breast Cancer 3.4 Other Breast Cancer Therapies 3.5 Market Dynamics 3.5.1 Drivers 3.5.1.1 Higher Incidence Rate 3.5.1.2 Demographic Transition 3.5.1.3 Rising Prevalence Of Obesity 3.5.1.4 Diagnostic Screening Programs 3.5.1.5 Increase in Private Health Insurance Plans: 3.5.2 Restraints 3.5.2.1 Generic Drugs: Substitute Branded Drugs 3.5.2.2 Intense Competition: Fall in Prices 3.5.2.3 Access barriers due to high drug costs 3.5.2.4 Absence of Social Health Insurance 3.5.2.5 Serious Side Effects of Breast Cancer Therapeutics 3.5.2.6 Countries Lacking Women Empowerment 3.5.3.7 Newer medication options 3.5.3 Opportunities 3.5.3.1 Potential Growth of Domestic Pharmaceutical Companies 3.5.3.2 Combination Drug Therapy 3.5.3.3 Technological Advancements and Robust Trends of Drug Approval 3.5.3.4 New Companion Diagnostics Models 3.5.3.5 Drug Therapy for Triple Negative (TNBC) 3.5.3.6 Approval for Multiple Indications (positive & negative types) HER2 breast cancer 3.7 Market Attractiveness Analysis– Breast Cancer Therapeutics Market, by Geography 3.8 Competitive Landscape – Breast Cancer Therapeutics Market, by Key Players 4. GLOBAL BREAST CANCER THERAPEUTICS MARKET, BY DRUG CLASS 4.1 Overview 4.2 Global HER2 Inhibitors Market Revenue 4.2.1 Herceptin (Trastuzumab) 4.2.2 Tykerb (Lapatinib) 4.2.3 Perjeta (Pertuzumab) 4.2.4 Kadcyla (Ado-trastuzumab emtansine) 4.3 Global Mitotic Inhibitors Market Revenue 4.3.1 Halaven (Eribulin) 4.3.2 Taxotere (Docetaxel) 4.3.3 Ixempra (Ixabepilone) 4.4 Global Anti-metabolites Market Revenue 4.4.1 Gemzar (Gemcitabine) 4.5 Global Aromatase Inhibitors Market Revenue 4.5.1 Femara (Leterozole) 4.5.2 Aromasin (Exemestane) 4.5.3 Arimidex (Anastrozole) 4.5.4 Ibrance (Palbociclib) 4.5.5 Afinitor (Everolimus) 4.6 Global Hormone Receptor Market Revenue 4.6.1 Zoladex 4.6.2 Faslodex 4.6.3 Fareston 5. GLOBAL BREAST CANCER THERAPEUTICS MARKET, BY TECHNOLOGY 5.1 Chemotherapy 5.1.1Alkylating Agents 5.1.2Cytotoxic agents 5.1.3Antimetabolites 5.1.4Plant derivatives 5.1.5Others 5.2 Radiation Therapy 5.2.1Intraoperative radiotherapy, 5.2.2 External beam radiation therapy 5.2.3 Brachytherapy 5.2.4 Radioisotope therapy 5.3 Hormone Therapy 5.3.1Hormone antagonists 5.3.2 Corticosteroids 5.3.3 Aromatase inhibitor 5.3.4 Selective estrogen receptor modulators (SERMs) 5.4 Biotherapy 5.4.1 Monoclonal antibodies 5.4.2 Interleukin 5.4.3 Kinases 5.4.4Others 6. GLOBAL BREAST CANCER THERAPEUTICS MARKET, BY GEOGRAPHY 6.1 Introduction 6.2 North America 6.2.1 U.S. 6.2.2 Canada 6.3 Europe 6.3.1 Germany 6.3.2 France 6.3.3 U.K. 6.3.4 Italy 6.3.5 Spain 6.3.6 Russia 6.3.7 Rest of Europe (RoE) 6.4 Asia-Pacific (APAC) 6.4.1 Japan 6.4.2 China 6.4.3 India 6.4.4 Rest of Asia-Pacific (RoAPAC) 6.5 Latin America 6.5.1 Brazil 6.5.2 Argentina 6.5.3 Rest of Latin America (RoLA) 6.6 Middle East and Africa 7. COMPETITIVE LANDSCAPE 7.1 Overview 7.2 Market Share Analysis 7.3 Competitive Situation and Trends 7.4 New Product Launches 7.5 Agreements, Partnerships, and Collaborations 7.6 Acquisitions 7.7 Expansions 7.8 Other Strategies 8. COMPANY PROFILES 8.1 AstraZeneca plc 8.2 Eisai Co., Ltd. 8.3 Eli Lilly and Company 8.4 F. Hoffmann-La Roche Ltd. 8.5 GlaxoSmithKline plc 8.6 Novartis International AG 8.7 Pfizer, Inc. 8.8 Puma Biotechnology, Inc. 8.9 Sanofi S.A. 8.10 Teva Pharmaceutical Industries Ltd. 8.11 Genentech 8.12 Fresenius kabi 8.13 AbbVie, Inc. 8.14 Johnson & Johnson 8.15 Astellas Pharma, Inc. 8.16 Bayer AG 8.17 Takeda Pharmaceutical Company Limited

About This Report

Report ID3422
Category Life Science
Published DateAugust 2019
Updated DateNov 2020
Contact Us